Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Transplant. 2013 Nov;17(7):661-9. doi: 10.1111/petr.12131. Epub 2013 Aug 6.

Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients.

Author information

1
Department of Cardiology, Boston Children's Hospital, Boston, MA, USA.

Abstract

Sensitization to HLA is a risk factor for adverse outcomes after heart transplantation. Requiring a negative prospective CM results in longer waiting times and increased waitlist mortality. We report outcomes in a cohort of sensitized children who underwent transplant despite a positive CDC CM+ using a protocol of antibody depletion at time of transplant, followed by serial IVIG administration. All patients <21 yrs old who underwent heart transplantation at Boston Children's Hospital from 1/1998 to 1/2011 were included. We compared freedom from allograft loss, allograft rejection, and serious infection between CM+ and CM- recipients. Of 134 patients in the cohort, 33 (25%) were sensitized prior to transplantation and 12 (9%) received a CM+ heart transplant. Serious infection in the first post-transplant year was more prevalent in the CM+ patients compared with CM- patients (50% vs. 16%; p = 0.005), as was HD-AMR (50% vs. 2%; p < 0.001). There was no difference in freedom from allograft loss or any rejection. At our center, children transplanted despite a positive CM had acceptable allograft survival and risk of any rejection, but a higher risk of HD-AMR and serious infection.

KEYWORDS:

anti-HLA antibody; antibody-mediated rejection; infectious risk; outcome; pediatric heart transplantation; plasmapheresis

PMID:
23919762
PMCID:
PMC3843490
DOI:
10.1111/petr.12131
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center